Intensive retreatment of adults and children with acute lymphoblastic leukemia.

abstract：:The aim of this article is to meta-analyse published data about the detection rate (DR) of fluorine-18-fluorodeoxyglucose ((18) F-FDG) positron emission tomography (PET) and PET/computed tomography (CT) in the evaluation of patients with marginal zone lymphoma of the mucosa-associated lymphoid tissue (MALT). A compreh...

journal_title：Hematological oncology

authors： Treglia G,Zucca E,Sadeghi R,Cavalli F,Giovanella L,Ceriani L

更新日期：2015-09-01 00:00:00

abstract：:Pediatric-type follicular lymphoma (PTFL), pediatric nodal marginal zone lymphoma (pnMZL), and large B-cell lymphoma (LBCL) with IRF4 rearrangement have been introduced into the current World Health Organization (WHO) classification. They account for 5% to 10% of mature B-cell lymphomas in children and adolescents. Bo...

journal_title：Hematological oncology

authors： Woessmann W,Quintanilla-Martinez L

更新日期：2019-06-01 00:00:00

abstract：:Imatinib mesylate, binding to the inactive conformation of Bcr-Abl tyrosine kinase and suppressing the Ph chromosome positive clone, has revolutionized the treatment of chronic myeloid leukaemia (CML) patients. Given the high rates of clinical and cytogenetic remission achieved, the molecular monitoring of BCR-ABL tra...

journal_title：Hematological oncology

authors： Martinelli G,Iacobucci I,Soverini S,Cilloni D,Saglio G,Pane F,Baccarani M

更新日期：2006-12-01 00:00:00

abstract：:Fourteen patients with poor-risk acute myelogenous leukaemia (AML) and five patients with accelerated phase/blast crisis chronic myeloid leukaemia (CML) were treated with 3 days of oral idarubicin (25 mg/m2/day). No complete remissions or return to chronic phase CML were observed. A fall in the peripheral blast count ...

journal_title：Hematological oncology

authors： Malik ST,Tucker J,Rohatiner AZ,Brace W,Lister TA

更新日期：1989-11-01 00:00:00

abstract：:Translocations at the immunoglobulin heavy chain locus (14q32) are now considered the commonest karyotypic change in multiple myeloma. These translocations are thought to be intimately involved in the pathogenesis of this disease. The heavy chain locus is strongly transcriptionally active in B and plasma cells and tra...

journal_title：Hematological oncology

authors： Fenton JA,Pratt G,Rawstron AC,Morgan GJ

更新日期：2002-06-01 00:00:00

abstract：:Bone marrow (BM) is accepted as the tissue of choice for the detection of monoclonal populations in leukemias and lymphomas; however, obtaining BM can be painful and traumatic for the patients. Although it is possible to detect clonality in peripheral blood (PB) samples, there are no reports comparing the results obse...

journal_title：Hematological oncology

authors： Leal E,Esparza-Flores MA,López-Guido B,Aguilar-Luna C,Aguilar-López L,Jaloma-Cruz AR,Medina C,Barros-Núñez P

更新日期：2003-03-01 00:00:00

abstract：:Primary CNS lymphoma (PCNSL) is an aggressive brain tumor that represents a significant challenge both to elucidate its biological pathogenesis as well as to develop definitive precision medicines with minimal collateral toxicity. We highlight the key issues in diagnosis and treatment and focus on emerging technologie...

journal_title：Hematological oncology

authors： Tsang M,Cleveland J,Rubenstein JL

更新日期：2020-12-01 00:00:00

abstract：:This paper presents a new analysis of aspects of the descriptive epidemiology of multiple myeloma (MM) for parts of the U.K., 1984-1993. It provides no indication for geographical heterogeneity, nor is there evidence of a decline in rates over the decade. There is, however, evidence that cancer registration inflates M...

journal_title：Hematological oncology

authors： Cartwright RA,Gilman EA,Nicholson P,Allon D

更新日期：1999-03-01 00:00:00

abstract：:There is a high incidence of genomic aberration of ataxia telangiectasia mutated (ATM) and genes encoding proteins involved in the ATM pathway in mantle cell lymphoma (MCL). It has been shown that poly(ADP-ribose) polymerase inhibitor (PARPi) strongly enhances the cytotoxicity of agents, causing single-strand DNA brea...

journal_title：Hematological oncology

authors： Golla RM,Li M,Shen Y,Ji M,Yan Y,Fu K,Greiner TC,McKeithan TW,Chan WC

更新日期：2012-12-01 00:00:00

abstract：:In 2009, the four laboratories of the Fondazione Italiana Linfomi (FIL) minimal residual disease (MRD) Network started a collaborative effort to harmonize and standardize their methodologies at the national level, performing quality control (QC) rounds for follicular lymphoma (FL) and mantle cell lymphoma (MCL) MRD as...

journal_title：Hematological oncology

authors： Della Starza I,Cavalli M,De Novi LA,Genuardi E,Mantoan B,Drandi D,Barbero D,Ciabatti E,Grassi S,Gazzola A,Mannu C,Agostinelli C,Piccaluga PP,Bomben R,Degan M,Gattei V,Guarini A,Foà R,Galimberti S,Ladetto M,Ferrero

更新日期：2019-10-01 00:00:00

abstract：:Multiple myeloma (MM) is the most common hematologic malignancy in Europe. Although remaining an incurable disease, substantial progress has been made within the last two decades. However, until recently, improvement in overall survival (OS) was only documented in younger, transplant-eligible patients. In this analysi...

journal_title：Hematological oncology

authors： Mey UJ,Leitner C,Driessen C,Cathomas R,Klingbiel D,Hitz F

更新日期：2016-12-01 00:00:00

abstract：:Langerhans cell histiocytosis (LCH) is a proliferative disease of CD1a+ /CD207+ dendritic cells. Recurrent BRAFV600E and MAP2K1 mutations have been reported in LCH. To investigate the relationship among the mutation, clinical findings, and differentiation status of LCH, respectively, we studied 97 cases of LCH by usin...

journal_title：Hematological oncology

authors： Zeng K,Ohshima K,Liu Y,Zhang W,Wang L,Fan L,Li M,Li X,Wang Z,Guo S,Yan Q,Guo Y

更新日期：2017-12-01 00:00:00

abstract：:This multicentre study focused on monitoring imatinib mesylate (IMA) trough plasma (Ctrough ) and intracellular (IMA Cintrac ) concentrations in 228 chronic myelogenous leukaemia patients. The median of measured IMA Ctrough in our patient group was 905.8 ng ml (range: 27.7-4628.1 ng/ml). We found a correlation between...

journal_title：Hematological oncology

authors： Racil Z,Razga F,Klamova H,Voglova J,Belohlavkova P,Malaskova L,Potesil D,Muzik J,Zackova D,Polakova KM,Zdrahal Z,Malakova J,Suttnar J,Dyr J,Mayer J

更新日期：2014-06-01 00:00:00

abstract：:The prognosis of diffuse large B-cell lymphoma (DLBCL) having MYC rearrangement (MYC-R), including double hit lymphoma (DHL), is poor by standard immunochemotherapy. To evaluate the significance of hematopoietic stem cell transplantation (SCT) for DLBCL with MYC-R, we retrospectively analyzed Japanese SCT registry dat...

journal_title：Hematological oncology

authors： Takahashi T,Suzuki R,Yamamoto G,Nakazawa H,Kurosawa M,Kobayashi T,Okada M,Akasaka T,Kim SW,Fukuda T,Ichinohe T,Atsuta Y,Suzumiya J

更新日期：2020-09-26 00:00:00

abstract：:Previous studies have shown that the incidence of non-Hodgkin's lymphoma (NHL) has increased in many parts of the world in recent decades. Using data obtained from the Canadian Cancer Registry, the present study examined time trends in NHL incidence in Canada between 1970 and 1996 and the effects of age, period of dia...

journal_title：Hematological oncology

authors： Liu S,Semenciw R,Mao Y

更新日期：2003-06-01 00:00:00

abstract：:B-cell post-transplant lymphoproliferative disorders (PTLD) are classified as early lesions, polymorphic lymphomas (P-PTLD) and monomorphic lymphomas (M-PTLD). These morphologic categories are thought to reflect a biologic continuum, although supporting genetic data are lacking. To gain better insights into PTLD patho...

journal_title：Hematological oncology

authors： Vakiani E,Basso K,Klein U,Mansukhani MM,Narayan G,Smith PM,Murty VV,Dalla-Favera R,Pasqualucci L,Bhagat G

更新日期：2008-12-01 00:00:00

abstract：:During the formation of the Philadelphia (Ph) chromosome, in the majority of chronic myelogenous leukemia (CML) patients, the chromosome 22 breakpoint is located in the major breakpoint cluster region of the BCR gene (M-bcr). Minor and micro breakpoint cluster regions (m-bcr with e1a2 transcript and micro-bcr with e19...

journal_title：Hematological oncology

authors： Andrikovics H,Nahajevszky S,Szilvási A,Bors A,Adám E,Kozma A,Kajtár B,Barta A,Poros A,Tordai A

更新日期：2007-09-01 00:00:00

abstract：:Bendamustine and rituximab (BR) are widely used in patients with follicular lymphoma (FL) previously treated with conventional immunochemotherapy, but the role of consolidation radioimmunotherapy in these patients is unknown. This study evaluated the efficacy and safety of consolidation with 90 Yttrium-ibritumomab tiu...

journal_title：Hematological oncology

authors： Miura K,Tsujimura H,Masaki Y,Iino M,Takizawa J,Maeda Y,Yamamoto K,Tamura S,Yoshida A,Yagi H,Yoshida I,Kitazume K,Masunari T,Choi I,Kakinoki Y,Suzuki R,Yoshino T,Nakamura S,Hatta Y,Yoshida T,Kanno M

更新日期：2020-09-25 00:00:00

abstract：:Post-transplant lymphoproliferative disorders (PTLD) are a major problem in transplant medicine. So far, the insights into pathogenesis and potentially druggable pathways in PTLD remain scarce. We investigated a cohort of PTLD patients, consisting of both polymorphic (n = 3) and monomorphic (n = 19) B-cell lymphoproli...

journal_title：Hematological oncology

authors： Menter T,Dickenmann M,Juskevicius D,Steiger J,Dirnhofer S,Tzankov A

更新日期：2017-06-01 00:00:00

abstract：:Fungal infection is a serious complication in immunocompromised patients, especially those with neutropenia. Itraconazole (ITZ) is expected to be an effective prophylactic agent for fungal infection because it has more activity against Aspergillus species than fluconazole and it is less toxic than amphotericin-B. Howe...

journal_title：Hematological oncology

authors： Kanda Y,Kami M,Matsuyama T,Mitani K,Chiba S,Yazaki Y,Hirai H

更新日期：1998-03-01 00:00:00

abstract：:Primary bone marrow lymphoma is a rare disease and remains undiagnosed due to deceptive clinical presentation. Here, we report four cases of primary bone marrow B-cell non-Hodgkin lymphoma, which presented with cytopenias without any lymphadenopathy or organomegaly. Bone marrow examination revealed large atypical B-ce...

journal_title：Hematological oncology

authors： Bhagat P,Sachdeva MU,Sharma P,Naseem S,Ahluwalia J,Das R,Varma N,Law A,Malhotra P

更新日期：2016-03-01 00:00:00

abstract：:One hundred and twenty-five cases of acute myeloid leukemia (AML) were reviewed for the presence of Auer rods by two peroxidase methods. The percentage of Auer rods recognized by Wright-Giemsa (WG) staining was 20.8% but three times higher by peroxidase staining techniques using either benzidine base as a substrate (P...

journal_title：Hematological oncology

authors： Jain NC,Cox C,Bennett JM

更新日期：1987-07-01 00:00:00

abstract：:Peripheral blood progenitor cells used during high dose treatments for malignancy may be contaminated with tumour cells that could later contribute to recurrence. CD34+ selected harvests still contain tumour cells and an additional negative selection may be capable of reducing this contamination. We have assessed a tw...

journal_title：Hematological oncology

authors： Davies FE,Rawstron AC,Pratt G,Coupe R,Clarke D,Lubenko A,Short K,Perren TJ,Selby PJ,Maclennan S,Major K,Woodhead V,Robinson F,Child JA,Smith GM,Johnson PW,Morgan GJ

更新日期：2000-09-01 00:00:00

abstract：:Mesenchymal stem cells (MSCs) are a subset of multifunctional stem cells with self-renewal and multidirectional differentiation properties that play a pivotal role in tumor progression. MSCs are reported to exert biological functions by secreting specialized vesicles, known as exosomes, with tumor cells. Exosomes part...

journal_title：Hematological oncology

authors： Lyu T,Zhang B,Li M,Jiao X,Song Y

更新日期：2020-08-27 00:00:00

abstract：:These are the final results of the Ofatumumab in MALT lymphoma study (O-MA 1), a pilot phase II trial evaluating the capacity and safety of ofatumumab to induce objective responses in patients with Helicobacter pylori eradication refractory or extragastric MALT lymphoma. Ofatumumab was given at 4 weekly doses (1000 mg...

journal_title：Hematological oncology

authors： Kiesewetter B,Neuper O,Mayerhoefer ME,Dolak W,Lukas J,Simonitsch-Klupp I,Raderer M

更新日期：2018-02-01 00:00:00

abstract：:Fourteen patients with Hodgkin's disease (two previously untreated, 12 following relapse or with refractory disease) were treated with a combination chemotherapy regimen comprising chlorambucil, vinblastine, procarbazine, prednisolone, etoposide, vincristine and adriamycin administered on days 1-8. Recombinant human g...

journal_title：Hematological oncology

authors： Oza AM,Leahy M,Dorey E,Davis CL,Amess J,Horton M,Rohatiner AZ,Wrigley PF,Lister TA

更新日期：1991-11-01 00:00:00

abstract：:Follicular lymphoma is characterized by a good response to immunochemotherapy (ICT). However, a small percentage of patients responds poorly to treatment and seems to have a worse outcome. This study attempted to identify the predictive factors and outcome of refractoriness to first-line ICT. All patients diagnosed wi...

journal_title：Hematological oncology

authors： Sorigue M,Mercadal S,Alonso S,Fernández-Álvarez R,García O,Moreno M,Pomares H,Alcoceba M,González-García E,Motlló C,González-Barca E,Martin A,Sureda A,Caballero D,Ribera JM,Sancho JM

更新日期：2017-12-01 00:00:00

abstract：:The cause of myelosuppression in hairy cell leukemia (HCL) has been ascribed to a reduction of the circulating progenitor cell (CPC) compartment and to suppression of hematopoiesis by TNF-alpha. The present study was performed to evaluate the inhibitory effect of hairy cells (HCs) and a possible lack of hematopoietic ...

journal_title：Hematological oncology

authors： Gasché C,Reinisch W,Schwarzmeier JD

更新日期：1993-03-01 00:00:00

abstract：:Data about treatment outcomes and toxicity in Latin America are scarce. There are differences with central countries based on access to healthcare system and socioeconomic status. Argentinean Society of Hematology recommends bortezomib-based triplets for induction treatment of transplant eligible newly diagnosed multi...

journal_title：Hematological oncology

authors： Schütz NP,Ochoa P,Duarte P,Remaggi G,Yantorno S,Corzo A,Zabaljauregui S,Shanley C,Lopresti S,Orlando S,Verri V,Quiroga L,García CA,Fernández V,Fantl D

更新日期：2020-08-01 00:00:00

abstract：:This study evaluates response-adapted treatment of chronic myelogenous leukaemia (CML) in chronic phase using molecular response criteria. bcr-abl/G6PDH ratios were assessed by Light-Cycler quantitative real-time polymerase chain reaction (PCR( in 277 peripheral blood samples from 33 patients, before and every 3 month...

journal_title：Hematological oncology

authors： Neumann F,Markett J,Fenk R,Pooten M,Koch A,Bruennert D,Schimkus N,Wulfert M,Royer-Pokora B,Kronenwett R,Haas R,Gattermann N

更新日期：2008-12-01 00:00:00